| Budget Amount *help |
¥4,810,000 (Direct Cost: ¥3,700,000、Indirect Cost: ¥1,110,000)
Fiscal Year 2017: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2016: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2015: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
|
|---|
| Outline of Final Research Achievements |
In this study，we focused on the mechanism how the synovial sarcoma cells escape from immune surveillance and found that MICA/B molecules in synovial sarcoma cells were disappeared when the cells were in hypoxia and floating conditions. Twist1 transcription factor also depressed MICA/B expression. On the other hand, low-dose of HDAC inhibitors markedly up-regulated MICA/B expression. MICA/B expression was N-glycosylation sensitive and tunicamycin treatment rapidly killed MICA/B expression. We also found that MICA/B negative synovial sarcoma cells was also sensitive to HDAC inhibitor treatment and confirmed weak MICA/B protein expression. Here, we found that MICA/B mRNA sequence in MICA/B negative cells were not uniform and most of that disrupted N-glycosylation site in protein level. In conclusion, low-dose of HDAC inhibitor treatment could improve anti-tumor-effect by NK cells by MICA/B stimulation.
|
